Author: Nicole Sario

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

With the acquisition of Abbott Laboratories' (ABT) non-US developed markets specialty and branded generics business, Mylan relocated its headquarters to the Netherlands.

Teva beat Wall Street adjusted EPS estimates of $1.25 by a wide margin, posting $1.36 EPS. This represents a growth of ~9%.

A lower effective tax rate and share repurchases had a positive impact on EPS. The company has consistently beaten Wall Street analysts’ EPS estimates for the last eight quarters.

Novartis (NVS) posted its 1Q15 earnings on April 23. Novartis beat Wall Street adjusted earnings per share estimates of $1.06, posting $1.29, a 21.7% growth.

Johnson & Johnson (JNJ) posted its 1Q15 earnings on April 14. It beat Wall Street EPS estimates of $1.53 marginally, posting $1.56 EPS.

According to Wall Street estimates, Teva earnings per share will be $1.25 for the first quarter of 2015, a rise of ~3% over the same quarter in 2014.

Mylan will benefit from Abbott’s commercial infrastructure that includes a workforce of 2,000 sales representatives as well as manufacturing units in Japan and France.

Teva Pharmaceutical Industries Ltd. (TEVA) is a leader in the global generics pharmaceutical industry on the basis of revenues of ~$20 billion in 2014.

In 2014, Actavis generated revenue of $13,062.3 million, employed 21,600 workers, and had more than 30 manufacturing and distribution facilities worldwide.

The prescription drug market is divided into two categories—branded or generic drugs. Branded drugs are patented drugs. Generics are off-patented drugs.